Russia's Biocad to file lawsuit against Roche in US court
Leading Russian biotech firm Biocad has filed a petition to the New York Federal Court against Swiss pharma giant Roche (ROG: SIX), accusing the company of setting monopoly-low prices for its products in Russia, with the aim ofruining business of local competitors, reports The Pharma Letter’s local correspondent.
According to Biocad, Roche currently uses the practice of artificial reduction of prices for its anti-cancer drugs Avastin (bevacizumab), Herceptin (trastuzumab) and Rituxan/MabThera (rituximab), which make biosimilars of these drugs produced by Biocad uncompetitive.
A spokesman of Biocad said that the current actions of Roche also prevent the expansion of Biocad with these drugs in the foreign markets, and in particular the USA. In the US case, according to Biocad, Roche’s exclusive rights on all the three drugs expire in 2018-2019.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze